miR-125 protects the body from steatosis and insulin resistance through its suppression of genes involved in lipogenesis. Exosomal miR-125a/b was reduced in glucagon-like peptide-2 (GLP-2)-treated rat residual jejunum tissue, and mediated the intestinotrophic effect of GLP-2 via elevating the levels of target molecule, myeloid cell leukemia-1 (MCL1) [41]. The gene discussed is MCL1; the disease is Insulin resistance.